International Journal of Hematology and Oncology
2025, Vol 35, Num 3 Page(s): 159-165
| Back | Table of Contents | PDF | Mail to Author | |
The Effect of PET/CT SUV max Value on Anti-EGFR Treatment Response in Lung Adenocarcinoma
Ozlem ERCELEP1, Selver ISIK1, Ece ERCAN2, Osman KOSTEK3, Vedat BAYOGLU3, Abdussamet CELEBI3, Nadiye SEVER3, Nergiz MECIDOVA3, Erkam KOCAASLAN3, Pinar EREL3, Yesim AGYOL3, Ali Kaan GUVEN3, Feyza SEN4, Derya KOCAKAYA5, Emine BOZKURTLAR5, Rukiye ARIKAN1, Murat SARI3
1Marmara University Pendik Training and Research Hospital, Department of Medical Oncology
2Marmara University Faculty of Medicine, Department of Radiation Oncology
3Marmara University Faculty of Medicine, Department of Medical Oncology
4Marmara University Faculty of Medicine, Department of Nuclear Medicine
5Marmara University Faculty of Medicine, Department of Pulmonary Medicine
6Marmara University Faculty of Medicine, Department of Pathology
Keywords: Lung cancer, Adenocarcinoma, EGFR TKI, PET/CT, SUV max
In this study, we aimed to evaluate the effect of pre-treatment positron emission tomography-computed tomography (PET/CT) maximum standardized uptake value (SUV max) on the response to tyrosine kinase inhibitor (TKI) treatment and survival in patients with metastatic lung adenocarcinoma. We retrospectively evaluated data from 77 patients diagnosed with advanced-stage lung adenocarcinoma, who had activating EGFR mutations and received first-line anti-EGFR TKI treatment between 2011 and 2022. We determined the effect of the PET/CT SUV max value on the anti-EGFR TKI treatment response by identifying a cut-off with ROC analysis. Median age was 63 years (range 30-86), 46 patients were female (59.7%). Median follow-up time was 24 months (range 3-122), median overall survival (OS) was 25 months, median progression-free survival (PFS) was 14 months, and the median SUV max was 9 (range 2-35). Ideal cut-off value of pretreatment SUV max that predicted 1-year PFS was 9 in the ROC analysis [AUC: 0.649 (0.524-0.774) / p= 0.025] with a sensitivity of 65% and specificity of 65%. While the >1-year PFS rate was 65% in patients with pretreatment SUV max ≤ 9, it was 35% in patients with SUV max > 9 (p= 0.012). Patients with a pretreatment PET/CT SUV max median ≤ 9 had significantly longer median PFS (18 months vs. 11 months) (p= 0.038) and median OS (30 months vs. 20 months) (p= 0.023) compared to those with SUV max median > 9. An increase in baseline PET/CT SUV max value before treatment negatively predicts response to anti-EGFR treatments, PFS, and OS.
Ozlem ERCELEP1, Selver ISIK1, Ece ERCAN2, Osman KOSTEK3, Vedat BAYOGLU3, Abdussamet CELEBI3, Nadiye SEVER3, Nergiz MECIDOVA3, Erkam KOCAASLAN3, Pinar EREL3, Yesim AGYOL3, Ali Kaan GUVEN3, Feyza SEN4, Derya KOCAKAYA5, Emine BOZKURTLAR5, Rukiye ARIKAN1, Murat SARI3
1Marmara University Pendik Training and Research Hospital, Department of Medical Oncology
2Marmara University Faculty of Medicine, Department of Radiation Oncology
3Marmara University Faculty of Medicine, Department of Medical Oncology
4Marmara University Faculty of Medicine, Department of Nuclear Medicine
5Marmara University Faculty of Medicine, Department of Pulmonary Medicine
6Marmara University Faculty of Medicine, Department of Pathology
Keywords: Lung cancer, Adenocarcinoma, EGFR TKI, PET/CT, SUV max
In this study, we aimed to evaluate the effect of pre-treatment positron emission tomography-computed tomography (PET/CT) maximum standardized uptake value (SUV max) on the response to tyrosine kinase inhibitor (TKI) treatment and survival in patients with metastatic lung adenocarcinoma. We retrospectively evaluated data from 77 patients diagnosed with advanced-stage lung adenocarcinoma, who had activating EGFR mutations and received first-line anti-EGFR TKI treatment between 2011 and 2022. We determined the effect of the PET/CT SUV max value on the anti-EGFR TKI treatment response by identifying a cut-off with ROC analysis. Median age was 63 years (range 30-86), 46 patients were female (59.7%). Median follow-up time was 24 months (range 3-122), median overall survival (OS) was 25 months, median progression-free survival (PFS) was 14 months, and the median SUV max was 9 (range 2-35). Ideal cut-off value of pretreatment SUV max that predicted 1-year PFS was 9 in the ROC analysis [AUC: 0.649 (0.524-0.774) / p= 0.025] with a sensitivity of 65% and specificity of 65%. While the >1-year PFS rate was 65% in patients with pretreatment SUV max ≤ 9, it was 35% in patients with SUV max > 9 (p= 0.012). Patients with a pretreatment PET/CT SUV max median ≤ 9 had significantly longer median PFS (18 months vs. 11 months) (p= 0.038) and median OS (30 months vs. 20 months) (p= 0.023) compared to those with SUV max median > 9. An increase in baseline PET/CT SUV max value before treatment negatively predicts response to anti-EGFR treatments, PFS, and OS.
| Back | Table of Contents | PDF | Mail to Author | |